Hike in medication price leads to drop in demand
As expenses mount, patients will look for alternatives, no matter how popular or useful the product
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
EARLY last year, drugmaker Mallinckrodt plc spent US$1.3 billion to buy a company that sold an injectable form of acetaminophen - essentially Tylenol in a liquid solution.
Within months, the new owner more than doubled the price of the drug, called Ofirmev. Revenue from the medication shot up, too, and hospitals searched for ways to absorb the costs - large hospital systems such as Johns Hopkins Medicine and New York University Langone Medical Center said that their expenses surged US$1 million a year or more.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
